- ►annals.org [PDF] S Eshaghian, S Kaul, S Amin, PK Shah, GA … - Annals of Internal Medicine, 2007 - Am Coll Physicians Aspirin is the most widely used antiplatelet agent for preventing and treating
vascular events. The thienopyridine derivatives, ticlo- pidine and clopidogrel,
are a suitable alternative in patients who are intolerant to aspirin, and ... Cited by 19 - Related articles - BL Direct - All 10 versions
[CITATION] for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study …
K Cassar, P Bachoo, I Ford, M Greaves, J … - Journal of Vascular Surgery, 2005 - Elsevier Coagulation activation markers are significantly elevated in patients with
peripheral arterial disease compared with healthy controls. The more severe the
disease, the higher the markers. Increased coagulation activation may ... Cited by 6 - Related articles - All 3 versions
VL Serebruany, AI Malinin, D Atar, DF Hanley - American Heart Journal, 2007 - Elsevier Numerous reports have dichotomized responses after clopidogrel therapy using
varying definitions and platelet tests in patients immediately after acute
vascular events; however, no large study has assessed platelet ... Cited by 7 - Related articles - All 15 versions
A Undas, M Celinska-Lowenhof, E St pien, R … - THROMBOSIS AND HAEMOSTASIS-STUTTGART-, 2006 - schattauer.de Effects of simvastatin on angiogenic growth factors released at the site of
microvascular injury ... Anetta Undas1,2, Magdalena Celinska-Lowenhoff1, Ewa
Stïpien2, Rafal Niz ... Andrzej Szczeklik1 1Department of Medicine and ... Cited by 10 - Related articles - BL Direct - All 5 versions
C Stellbaum, T Willich, U Boltzen, Y Ayral, B … - European journal of haematology, 2007 - pt.wkhealth.com Background: Tissue factor (TF), the initiator of coagulation, circulates in
blood and contributes to thrombosis in patients with coronary artery disease
(CAD). TF is present in the α-granules of platelets. Therapy with ... Cited by 10 - Related articles - BL Direct - All 5 versions
J Dropinski, J Musial, B Jakiela, W Wegrzyn, … - Thrombosis and haemostasis, 2005 - ncbi.nlm.nih.gov Individual variability in response to clopidogrel is known but its mechanism is
poorly understood. We examined the relationship between glycoprotein IIIa
polymorphism P1(A1/A2) and anti-thrombotic actions of clopidogrel. ... Cited by 12 - Related articles - BL Direct - All 2 versions
PA Gurbel, KP Bliden, K Guyer, N Aggarwal, … - Thrombosis research, 2007 - Elsevier Using thrombelastography (TEG®) we measured the time to platelet–fibrin clot
formation (R), a marker of the speed of thrombin generation, in 120 patients
undergoing elective coronary artery stenting treated with standard and high ... Cited by 12 - Related articles - All 8 versions
A Weltermann, P Fritsch, PA Kyrle, V … - Thrombosis research, 2003 - Elsevier Background: Current data suggest that pretreatment with clopidogrel (in addition
to aspirin) prior to elective percutaneous coronary intervention (PCI) might be
associated with a reduced incidence of subsequent adverse ischemic events. ... Cited by 12 - Related articles - All 12 versions
- ►hematologylibrary.org A Undas, KE Brummel-Ziedins, KG Mann - Blood, 2007 - bloodjournal.hematologylibrary.org Aspirin is effective in the prevention of cardiovascular events in high-risk
patients. The primary established effect of aspirin on hemostasis is to impair
platelet aggregation via inhibition of platelet thromboxane A 2 synthesis, ... Cited by 31 - Related articles - BL Direct - All 7 versions
